[
  {
    "ts": "2026-01-15T04:13:06+00:00",
    "headline": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
    "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-novo-nordisk-reshapes-its-strategy-under-new-ceo/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "b414eda8-cf17-37cb-b7c9-c6c1464a5b8e",
      "content": {
        "id": "b414eda8-cf17-37cb-b7c9-c6c1464a5b8e",
        "contentType": "STORY",
        "title": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
        "description": "",
        "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
        "pubDate": "2026-01-15T04:13:06Z",
        "displayTime": "2026-01-15T04:13:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m9hRgcHsaxFnPMapF7dREg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y6HX0lxrpZR4ULhZqw1OVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-novo-nordisk-reshapes-its-strategy-under-new-ceo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-novo-nordisk-reshapes-strategy-041306688.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T04:04:58+00:00",
    "headline": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
    "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-enters-2026-with-strong-momentum-given-pipeline-innovation/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "275e6e24-e9e1-3e83-b111-03bc2891eb1a",
      "content": {
        "id": "275e6e24-e9e1-3e83-b111-03bc2891eb1a",
        "contentType": "STORY",
        "title": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
        "description": "",
        "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
        "pubDate": "2026-01-15T04:04:58Z",
        "displayTime": "2026-01-15T04:04:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L91cjHFSZBMXC6h1bBPvVA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ShFiCgASkTfyaCE7q2Kwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-enters-2026-with-strong-momentum-given-pipeline-innovation/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-eli-lilly-enters-2026-040458178.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T12:41:27+00:00",
    "headline": "Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues",
    "summary": "Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder",
    "url": "https://finance.yahoo.com/news/market-chatter-sanofi-disc-medicine-124127742.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "3453a452-44b3-3569-bd87-656c622f9743",
      "content": {
        "id": "3453a452-44b3-3569-bd87-656c622f9743",
        "contentType": "STORY",
        "title": "Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues",
        "description": "",
        "summary": "Sanofi (SNY) and Disc Medicine (IRON) saw reviews for their type 1 diabetes and rare blood disorder",
        "pubDate": "2026-01-15T12:41:27Z",
        "displayTime": "2026-01-15T12:41:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-sanofi-disc-medicine-124127742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-sanofi-disc-medicine-124127742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "IRON"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T13:28:05+00:00",
    "headline": "Alexandria Real Estate Equities, Inc. (ARE): A Bear Case Theory",
    "summary": "We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bears’ thesis on ARE. Alexandria Real Estate Equities, Inc.’s share was trading at $54.64 as of January 13th. ARE’s trailing and forward P/E were 150.89 and 16.69 respectively according to Yahoo […]",
    "url": "https://finance.yahoo.com/news/alexandria-real-estate-equities-inc-132805099.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a68628fd-ff52-3af1-8f30-7e0cfbbbd78f",
      "content": {
        "id": "a68628fd-ff52-3af1-8f30-7e0cfbbbd78f",
        "contentType": "STORY",
        "title": "Alexandria Real Estate Equities, Inc. (ARE): A Bear Case Theory",
        "description": "",
        "summary": "We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bears’ thesis on ARE. Alexandria Real Estate Equities, Inc.’s share was trading at $54.64 as of January 13th. ARE’s trailing and forward P/E were 150.89 and 16.69 respectively according to Yahoo […]",
        "pubDate": "2026-01-15T13:28:05Z",
        "displayTime": "2026-01-15T13:28:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/799654f0608780ea586c21e56825c04b",
          "originalWidth": 1280,
          "originalHeight": 851,
          "caption": "Top 5 Ivy League Colleges for Pre-Med",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PnKMb7f0mnBhgN0lpEiLOQ--~B/aD04NTE7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/799654f0608780ea586c21e56825c04b.cf.webp",
              "width": 1280,
              "height": 851,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XUQ9vqZSV6.Y0ANGHO0RlA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/799654f0608780ea586c21e56825c04b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/alexandria-real-estate-equities-inc-132805099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/alexandria-real-estate-equities-inc-132805099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]